Company Overview
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Why Investors Should Care
Revenue has grown at a 12.9% CAGR over the past five years.
Recent Developments
- Aug 2025 Revenue of $705.92K (+52.0% YoY); net profit $-11.90M.
- Trailing 12 Months Year-on-year growth — revenue +52.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.92% |
| 1 Year: | 52.05% |
Stock Price Performance
| 1 Year: | -24.74% |
| 6 Months: | -14.43% |
| 3 Months: | -3.45% |
| 1 Month: | +77.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)46.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.9% over 5 years.
CONS
- Trading 59.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LEXX Lexaria Bioscience Corp. PHARMA | 9.37 | -1.84 | $19.74M | 0.00% | - | - | 12.92% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2014 | May 2014 | Jul 2014 | Nov 2014 | Feb 2015 | May 2015 | Nov 2015 | Feb 2016 | May 2016 | Nov 2016 | Feb 2017 | May 2017 | Nov 2017 | Feb 2018 | May 2018 | Nov 2018 | Feb 2019 | May 2019 | Nov 2019 | Feb 2020 | May 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Nov 2022 | Feb 2023 | May 2023 | Nov 2023 | Feb 2024 | May 2024 | Nov 2024 | Feb 2025 | May 2025 | Nov 2025 | Feb 2026 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 24.64K | 171.96K | 140.34K | 22.21K | 15.35K | 59.93K | 10.33K | 37.55K | 36.42K | 295.66K | 192.01K | 204.06K | - | 13.88K | - | - | 97.73K | - | - | 151.28K | - | - | 183.92K | - | - | - | - | - |
| Gross Profit | 57.54K | 0 | 53.76K | 0 | 831 | -2.50K | -3.60K | -4.08K | -3.09K | 8.34K | -2.27K | 20.07K | 18.54K | 158.25K | 137.91K | 20.05K | 12.66K | 56.84K | 2.48K | -20.56K | 16.10K | 231.18K | 161.44K | 144.07K | - | 8.31K | 24.26K | 81.08K | 81.94K | 17.07K | 64.96K | 146.46K | 145.00K | 84.00K | 181.20K | 174.00K | 174.00K | 0 | 20.00K | 0 |
| Operating Income | - | - | -567.95K | -398.07K | -458.61K | -511.01K | -411.74K | -274.56K | -264.20K | -400.55K | - | - | -578.71K | - | - | - | - | - | - | - | - | - | - | -2.57M | - | - | - | -2.42M | -1.70M | -1.32M | -2.40M | -1.14M | -668.00K | -1.74M | -2.69M | -2.75M | -3.75M | -1.57M | -1.45M | -1.99M |
| Net Income | - | - | - | -398.07K | - | - | -411.74K | - | - | - | - | - | -578.71K | - | - | -701.39K | - | - | -924.76K | -997.49K | -1.39M | -710.12K | 393.19K | -2.57M | -1.18M | -1.99M | -1.43M | -2.38M | -1.76M | -1.30M | -2.37M | -1.18M | -649.54K | -1.78M | -2.70M | -2.71M | -3.79M | -1.60M | -1.45M | -1.99M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.06 | -0.13 | -0.16 | -0.15 | -0.21 | -0.07 | -0.06 | -0.08 |
| R&D Expense | - | 0 | - | 48.04K | 240 | 107 | 1.98K | 6.85K | 158 | 7.26K | 7.78K | 8.24K | 110.39K | 75.76K | 93.07K | 96.97K | 66.08K | 231.03K | 107.46K | 186.56K | 24.56K | 192.26K | 176.40K | 454.44K | - | 458.71K | 275.69K | 752.10K | 829.49K | 696.18K | 1.64M | 574.49K | 245.78K | 573.09K | 1.95M | 1.69M | 2.72M | 671.34K | 475.39K | 970.83K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 14.70K | 40.72K | 63.64K | 433.29K | 222.61K | 384.54K | 722.74K | 255.40K | 226.21K | 464.28K | 705.92K |
| Gross Profit | 88.86K | 465.91K | 574.49K | 302.25K | 0 | -15.18K | -4.90K | 33.89K | 408.10K | 199.72K | 215.41K | 547.39K | 183.56K | 194.71K | 459.46K | 703.20K |
| Operating Income | - | - | - | - | -1.56M | -1.98M | -1.28M | - | - | - | - | -5.69M | -6.62M | -6.53M | -5.75M | -11.88M |
| Net Income | -552.46K | -538.23K | - | - | -1.56M | -1.98M | -1.28M | -1.93M | -6.61M | -4.16M | -4.08M | -4.03M | -7.27M | -6.66M | -5.80M | -11.90M |
| Diluted EPS | -0.04 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | -1.01 | -0.47 | -0.66 |
| R&D Expense | - | - | - | - | 0 | 146.47K | 9.02K | 54.19K | 492.86K | 555.73K | 387.07K | 1.26M | 1.84M | 3.67M | 2.36M | 8.24M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Aug 2013 | Oct 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.28M | 4.34M | 4.19M | - | 3.57M | 2.64M | 711.72K | 566.64K | 2.86M | 2.43M | 2.68M | 2.83M | 13.27M | 7.83M | 3.08M | 8.87M | 4.18M |
| Total Equity | 2.30M | 2.15M | 2.66M | 2.42M | - | 2.10M | 1.72M | 772.41K | 266.05K | 2.77M | 2.39M | 2.49M | 2.48M | 13.27M | 7.95M | 3.04M | 8.04M | 2.99M |
| Cash & Equivalents | 330.17K | 62.99K | 31.20K | 180.51K | 65.54K | 65.54K | 703.03K | 260.07K | 93.41K | 2.53M | 1.73M | 1.29M | 1.29M | 10.92M | 5.81M | - | - | - |
| Total Liabilities | - | 1.12M | 1.68M | 1.77M | - | 1.47M | 918.04K | 55.12K | 478.88K | 92.35K | 43.64K | 184.51K | 345.98K | 203.26K | 201.44K | 403.91K | 1.21M | 1.57M |
| Current Liabilities | - | 1.05M | 1.08M | 1.71M | - | 1.42M | 918.04K | 55.12K | 433.88K | 92.35K | 43.64K | 184.51K | 225.92K | 153.28K | 194.04K | 267.74K | 1.10M | 1.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -330.34K | 109.84K | 135.94K | 321.00K | -515.82K | -1.50M | -660.86K | -1.55M | -2.52M | -3.01M | -2.62M | -3.99M | -4.88M | -5.88M | -4.96M | -10.45M |
| Investing Cash Flow | -285.24K | -1.00M | -274.13K | -70.61K | -76.29K | 684.82K | -20.10K | -9.70K | -155.40K | -769.16K | -26.84K | 193.88K | -180.64K | -169.61K | -188.60K | -243.02K |
| Financing Cash Flow | 348.40K | 861.00K | 287.50K | -365.36K | 1.23M | 373.25K | 514.29K | 4.00M | 1.87M | 3.33M | 2.65M | 13.42M | -44.60K | 1.59M | 10.32M | 6.05M |
| Capital Expenditure | - | - | - | - | - | -0 | -3.09K | -0 | - | -646.18K | -0 | - | -49.19K | -33.75K | -43.01K | -24.65K |
| Free Cash Flow | - | - | - | - | - | -1.50M | -663.95K | -1.55M | - | -3.65M | -2.62M | - | -4.93M | -5.91M | -5.00M | -10.48M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | -103.3% | -12.0% | 53.3% | 94.2% | 89.7% | 56.0% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| Operating Margin % | - | - | - | - | - | -13,489.8% | -3,136.8% | - | - | - | - | -786.8% | -2,591.7% | -2,888.5% | -1,239.2% | -1,683.0% |
| Net Margin % | - | - | - | - | - | -13,489.8% | -3,136.8% | -3,031.9% | -1,525.4% | -1,868.0% | -1,062.2% | -557.2% | -2,846.3% | -2,946.4% | -1,248.2% | -1,686.0% |
| ROE % | -25.7% | -20.2% | - | - | -90.8% | -256.8% | -480.1% | -69.7% | -276.7% | -167.0% | -164.6% | -30.4% | -91.5% | -218.9% | -72.1% | -398.1% |
| ROCE % | - | - | - | - | -90.8% | -302.1% | -962.1% | - | - | - | - | -43.4% | -86.6% | -232.0% | -74.1% | -443.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Invenomic Capital Management, LP | 1.39% | 23.05K | $74.67K |
| 2 | Vanguard Capital Management LLC | 1.20% | 19.90K | $64.46K |
| 3 | Geode Capital Management, LLC | 1.01% | 16.69K | $54.09K |
| 4 | Citadel Advisors Llc | 0.63% | 10.46K | $33.90K |
| 5 | Toronto Dominion Bank | 0.40% | 6.67K | $21.60K |
| 6 | Vanguard Fiduciary Trust Co | 0.38% | 6.28K | $20.34K |
| 7 | HRT Financial LP | 0.26% | 4.34K | $14.05K |
| 8 | UBS Group AG | 0.19% | 3.13K | $10.14K |
| 9 | State Street Corporation | 0.16% | 2.62K | $8.49K |
| 10 | Northern Trust Corporation | 0.16% | 2.65K | $8.60K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LEXX
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxObzJ1R0ZtTVFDZTBhTEJkeERBWlRDWDVDcXUxNGNObjdzWmxabG1SYS1ZZTlfVHA1WTA1cjloVzV3ZEpfOHNWWDdvdm9FR2dWalJDNDUzSGtCMFppT3h5UnpoRHU0clNfU3NHbXZOUHF6NTVWd0FsejVhNkIxOFVhSHFRTm9ocnduWUNTTH…
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - investingnews.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOWXYxSmZMVEExWGVkVzZMSC02YTN1SG04S0E2T2xSemppcmNIZ24xdjR1d0d3NGxBU1dFTkFpRldwWERmZTFqWHpvNFNGTXlZWXFMeGdoSERkaXpvN2gtb3BkN01xa215OGlBU1BfN1lMNWxiekp5ZlhzSTBub0tNQ0FlQzM1YzNhR2V4MG…
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNMHoyVzI0SXNuOW5NZUZnNnNFcmdoNTJWUGVyYk9TTTBqZmRaSERkM28yY2JKNE1McnpFb1ZrcVptNzN3Tzk2dVFTMDB4c19zdzU4aG9Ya1pLN1A0NzBhME9hOGlycFRwQkcyYWw0M2xyRURHMWdreVltdmR6Qlk4OEs4cVd0RFcxSVlSWV…
(LEXX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOSTRvdm1XOTdjU2lJb0dlZUJCQTVJUV9UNTRXZmFPNkZUbXo0MG1WOVdvcnA4YUV5SjJtZFNIWTh0dVpZXzVYQlViYS12T04xaUs5NjlHYlBGOGRTYUpnWGswMkJJRUdxaFlfeHpCczk3NFctMHZFX1Zta0Ywb0FBWW1JOXQ1VWRxVHRfX0…
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNSTg2ZTBCc0ZfQjRCcDhRcjE4ajktX1hwZVpUSndxRGU3SnBfZUhUZnIxcldsYTM5NkI4QjRmQW00ckpkRE4zck0zRmExeFU5cHdESzU5N0ZzY0VDcHE4V0M5cnFNMnZ5eURuRkliN3JBazFOMEVVbXh3VEdhS3ZQdF9pWXN0clotUzhoVk…
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings | LEXX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQdnRvamxRaldLVS0zTE95SHkzenFxaFNCemItMlhrb2FKbGN1b3VVQjRRUzZaNkhYaG1IcjQxNk5kUVYtVGRwSTdQdTJHN3VfVVB5X05VdXczRlIyZFNMaHpjX3c1U1pLM1o2MHpyQXdFbDNrdERkXzR1YUZCREF3eE1WSkR4MFJDeVV3Yk…
LEXX — Frequently Asked Questions
What is the current share price of Lexaria Bioscience Corp. (LEXX)?
As of 2026-09-19 21:16 PDT, Lexaria Bioscience Corp. (LEXX) trades at $9.37 on NasdaqCM. Its 52-week range is $0.89 to $22.95.
What is the market capitalisation of LEXX?
Lexaria Bioscience Corp. (LEXX) has a market capitalisation of $19.74M on NasdaqCM.
What is the P/E ratio of LEXX?
LEXX trades at a trailing price-to-earnings (P/E) ratio of -1.84. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.13.
Is LEXX a good stock to buy?
This page provides a data-driven analysis of Lexaria Bioscience Corp. (LEXX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.